OncRef

Clinical Trial: NCT05680922

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Legend Biotech USA Inc
Information Provided By:Legend Biotech USA Inc
Last Update Posted:2026-03-24

Study Overview

Brief Summary

This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.

Official Title

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Conditions

Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung

Intervention / Treatment

  • Biological: LB2102

Other Study ID Numbers

  • LB2102-1001

Start Date (Actual)

2023-07-26

Primary Completion Date (Estimated)

2027-12

Study Completion Date (Estimated)

2027-12

Enrollment (Estimated)

41

Study Type

Interventional

Phase

Phase 1